AVANIR PHARMACEUTICALS
10-Q, EX-27.1, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: AVANIR PHARMACEUTICALS, 10-Q, EX-10.2, 2000-08-14
Next: FIRST COMMUNITY BANCSHARES INC /NV/, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S FORM 10-Q FOR THE NINE MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              SEP-30-2000
<PERIOD-START>                                 OCT-01-1999
<PERIOD-END>                                   JUN-30-2000
<CASH>                                          10,268,025
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                        225,353
<CURRENT-ASSETS>                                11,057,662
<PP&E>                                           1,029,446
<DEPRECIATION>                                    (542,026)
<TOTAL-ASSETS>                                  12,251,908
<CURRENT-LIABILITIES>                              832,125
<BONDS>                                                  0
                              455,010
                                              0
<COMMON>                                        81,251,336
<OTHER-SE>                                     (70,324,832)
<TOTAL-LIABILITY-AND-EQUITY>                    12,251,908
<SALES>                                                  0
<TOTAL-REVENUES>                                 1,213,646
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                 8,829,236<F1>
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                 346,220
<INCOME-PRETAX>                                 (7,961,810)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                             (7,961,810)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (7,961,810)
<EPS-BASIC>                                        (0.16)
<EPS-DILUTED>                                        (0.16)
<FN>
<F1> INCLUDES LITIGATION SETTLEMENT COSTS OF $4.1 MILLION, PAID WITH SHARES OF
COMMON STOCK
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission